(Q35689607)

9 August 2017

1 reference

title

A treatment algorithm for the management of chronic hepatitis B virus infection in the United States (English)

1 reference

9 August 2017

main subject

United States of America

0 references

1 reference

1 reference

1 reference

Emmet B Keeffe

1

1 reference

9 August 2017

Douglas T Dieterich

2

1 reference

9 August 2017

Steve-Huy B Han

3

1 reference

9 August 2017

Ira M Jacobson

4

1 reference

9 August 2017

Paul Martin

5

1 reference

9 August 2017

Eugene R Schiff

6

1 reference

9 August 2017

Hillel Tobias

7

1 reference

9 August 2017

Teresa L Wright

8

1 reference

9 August 2017

language of work or name

English

0 references

publication date

1 February 2004

1 reference

Clinical Gastroenterology and Hepatology

9 August 2017

published in

1 reference

9 August 2017

volume

2

1 reference

9 August 2017

issue

2

1 reference

9 August 2017

page(s)

87-106

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2803%2900312-4

9 August 2017

1 reference

7 January 2021

Management of chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2803%2900312-4

7 January 2021

Hepatitis B virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2803%2900312-4

7 January 2021

Prevalence of hepatitis B virus infection in the United States: the National Health and Nutrition Examination Surveys, 1976 through 1994

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2803%2900312-4

7 January 2021

Liver transplantation and hepatitis B

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2803%2900312-4

7 January 2021

Acute hepatitis B virus infection: relation of age to the clinical expression of disease and subsequent development of the carrier state

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2803%2900312-4

7 January 2021

Natural history of acute hepatitis B surface antigen-positive hepatitis in Greek adults

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2803%2900312-4

7 January 2021

Management of hepatitis B: 2000--summary of a workshop

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2803%2900312-4

7 January 2021

Hepatitis B virus deoxyribonucleic acid in liver of chronic carriers. Correlation with serum markers and changes associated with loss of hepatitis B e antigen after antiviral therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2803%2900312-4

7 January 2021

Acute flares in chronic hepatitis B: the natural and unnatural history of an immunologically mediated liver disease

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2803%2900312-4

7 January 2021

Survival and prognostic factors in 366 patients with compensated cirrhosis type B: a multicenter study. The Investigators of the European Concerted Action on Viral Hepatitis (EUROHEP)

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2803%2900312-4

7 January 2021

Survival and prognostic indicators in hepatitis B surface antigen-positive cirrhosis of the liver

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2803%2900312-4

7 January 2021

Hepatitis B e antigen and the risk of hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2803%2900312-4

7 January 2021

Mutation preventing formation of hepatitis B e antigen in patients with chronic hepatitis B infection.

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2803%2900312-4

7 January 2021

Hepatitis B e antigen-negative chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2803%2900312-4

7 January 2021

Wild-type and e antigen-minus hepatitis B viruses and course of chronic hepatitis.

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2803%2900312-4

7 January 2021

Genotype H: a new Amerindian genotype of hepatitis B virus revealed in Central America

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2803%2900312-4

7 January 2021

Genetic variability in hepatitis B viruses

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2803%2900312-4

7 January 2021

Clinical significance of hepatitis B virus genotypes

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2803%2900312-4

7 January 2021

Genotypes and clinical phenotypes of hepatitis B virus in patients with chronic hepatitis B virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2803%2900312-4

7 January 2021

Hepatitis B virus genotypes and hepatocellular carcinoma in Japan

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2803%2900312-4

7 January 2021

Hepatitis B virus genotype B is associated with earlier HBeAg seroconversion compared with hepatitis B virus genotype C.

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2803%2900312-4

7 January 2021

Hepatitis B genotypes and the response to interferon therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2803%2900312-4

7 January 2021

Long-term follow-up of HBeAg-positive patients treated with interferon alfa for chronic hepatitis B

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2803%2900312-4

7 January 2021

A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2803%2900312-4

7 January 2021

Hepatitis B virus. The major etiology of hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2803%2900312-4

7 January 2021

Serum Alpha-Fetoprotein Estimations and Doubling Time in Hepatocellular Carcinoma: Influence of Therapy and Possible Value in Early Detection

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2803%2900312-4

7 January 2021

Growth rate of asymptomatic hepatocellular carcinoma and its clinical implications

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2803%2900312-4

7 January 2021

Early detection of hepatocellular carcinoma by real-time ultrasonography. A prospective study

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2803%2900312-4

7 January 2021

Efficacy of a surveillance program for early detection of hepatocellular carcinoma.

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2803%2900312-4

7 January 2021

Screening for hepatocellular carcinoma in patients with Child's A cirrhosis: an 8-year prospective study by ultrasound and alphafetoprotein

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2803%2900312-4

7 January 2021

Hepatocellular carcinoma in Italian patients with cirrhosis

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2803%2900312-4

7 January 2021

EASL International Consensus Conference on Hepatitis B. 13-14 September, 2002: Geneva, Switzerland. Consensus statement (short version).

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2803%2900312-4

7 January 2021

Clinical, histological, and virological features of hepatitis C virus carriers with persistently normal or abnormal alanine transaminase levels

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2803%2900312-4

7 January 2021

Updated definitions of healthy ranges for serum alanine aminotransferase levels

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2803%2900312-4

7 January 2021

Pretherapy alanine transaminase level as a determinant for hepatitis B e antigen seroconversion during lamivudine therapy in patients with chronic hepatitis B. Asian Hepatitis Lamivudine Trial Group

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2803%2900312-4

7 January 2021

Predictors of HBeAg loss after lamivudine treatment for chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2803%2900312-4

7 January 2021

LONG-TERM FOLLOW-UP IN A RANDOMISED CONTROLLED TRIAL OF RECOMBINANT α2-INTERFERON IN CHINESE PATIENTS WITH CHRONIC HEPATITIS B INFECTION

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2803%2900312-4

7 January 2021

A controlled trial of interferon with or without prednisone priming for chronic hepatitis B

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2803%2900312-4

7 January 2021

Seroconversion from Hepatitis B e Antigen to Antibody in Chronic Type B Hepatitis

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2803%2900312-4

7 January 2021

Clinical, virologic and histologic outcome following seroconversion from HBeAg to anti-HBe in chronic hepatitis type B

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2803%2900312-4

7 January 2021

Persistent hepatitis B virus infection in subjects without hepatitis B surface antigen: clinically significant or purely "occult"?

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2803%2900312-4

7 January 2021

Occult hepatitis B virus infection: a hidden menace?

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2803%2900312-4

7 January 2021

Serum HBV DNA as a marker of efficacy during therapy for chronic HBV infection: analysis and review of the literature

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2803%2900312-4

7 January 2021

A longitudinal follow-up of asymptomatic hepatitis B surface antigen-positive chinese children

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2803%2900312-4

7 January 2021

Spontaneous hepatitis B e antigen to antibody seroconversion and reversion in Chinese patients with chronic hepatitis B virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2803%2900312-4

7 January 2021

Changes of serum hepatitis B virus DNA and aminotransferase levels during the course of chronic hepatitis B virus infection in children

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2803%2900312-4

7 January 2021

Acute exacerbations in Chinese patients with chronic hepatitis B virus (HBV) infection. Incidence, predisposing factors and etiology

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2803%2900312-4

7 January 2021

Long-term follow-up of interferon alfa treatment in Chinese patients with chronic hepatitis B infection: The effect on hepatitis B e antigen seroconversion and the development of cirrhosis-related complications

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2803%2900312-4

7 January 2021

Long-term outcome of chronic type B hepatitis in patients who acquire hepatitis B virus infection in childhood

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2803%2900312-4

7 January 2021

Effect of Alpha-Interferon Treatment in Patients with Hepatitis B e Antigen-Positive Chronic Hepatitis B

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2803%2900312-4

7 January 2021

Treatment algorithms for hepatitis B and C.

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2803%2900312-4

7 January 2021

Long term effect of alpha interferon in children with chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2803%2900312-4

7 January 2021

Delayed clearance of serum HBsAg in compensated cirrhosis B: relation to interferon alpha therapy and disease prognosis

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2803%2900312-4

7 January 2021

The treatment of chronic viral hepatitis

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2803%2900312-4

7 January 2021

Lamivudine as initial treatment for chronic hepatitis B in the United States

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2803%2900312-4

7 January 2021

Lamivudine and alpha interferon combination treatment of patients with chronic hepatitis B infection: a randomised trial

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2803%2900312-4

7 January 2021

Effects of extended lamivudine therapy in Asian patients with chronic hepatitis B. Asia Hepatitis Lamivudine Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2803%2900312-4

7 January 2021

Extended lamivudine treatment in patients with chronic hepatitis B enhances hepatitis B e antigen seroconversion rates: results after 3 years of therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2803%2900312-4

7 January 2021

Histological outcome during long-term lamivudine therapy.

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2803%2900312-4

7 January 2021

Management of YMDD mutations during lamivudine therapy in patients with chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2803%2900312-4

7 January 2021

Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2803%2900312-4

7 January 2021

Resistance to adefovir dipivoxil therapy associated with the selection of a novel mutation in the HBV polymerase

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2803%2900312-4

7 January 2021

Long-term remission of chronic hepatitis B after alpha-interferon therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2803%2900312-4

7 January 2021

The long-term effect of treatment with interferon-alpha 2a in chronic hepatitis B. The Long-Term Follow-up Investigator Group. The European Study Group on Viral Hepatitis (EUROHEP). Executive Team on Anti-Viral Treatment.

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2803%2900312-4

7 January 2021

Long-term beneficial effect of interferon therapy in patients with chronic hepatitis B virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2803%2900312-4

7 January 2021

Long-term follow-up of patients with chronic hepatitis B treated with interferon alfa

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2803%2900312-4

7 January 2021

Long-term follow-up of chronic hepatitis B patients treated with interferon alfa

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2803%2900312-4

7 January 2021

Durability of serologic response after lamivudine treatment of chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2803%2900312-4

7 January 2021

Hepatitis B e antigen seroconversion after lamivudine therapy is not durable in patients with chronic hepatitis B in Korea

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2803%2900312-4

7 January 2021

Long-term additional lamivudine therapy enhances durability of lamivudine-induced HBeAg loss: a prospective study

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2803%2900312-4

7 January 2021

Which patients with chronic hepatitis B virus infection will respond to alpha-interferon therapy? A statistical analysis of predictive factors

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2803%2900312-4

7 January 2021

Interferon alpha treatment and retreatment of hepatitis B e antigen-negative chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2803%2900312-4

7 January 2021

The long-term outcome of interferon-alpha treated and untreated patients with HBeAg-negative chronic hepatitis B

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2803%2900312-4

7 January 2021

Outcome of anti-HBe positive chronic hepatitis B in alpha-interferon treated and untreated patients: a long term cohort study

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2803%2900312-4

7 January 2021

Efficacy of lamivudine in patients with hepatitis B e antigen-negative/hepatitis B virus DNA-positive (precore mutant) chronic hepatitis B. Lamivudine Precore Mutant Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2803%2900312-4

7 January 2021

Long-term follow-up of patients with anti-HBe/HBV DNA-positive chronic hepatitis B treated for 12 months with lamivudine

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2803%2900312-4

7 January 2021

Efficacy of long-term lamivudine monotherapy in patients with hepatitis B e antigen-negative chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2803%2900312-4

7 January 2021

Two years of lamivudine therapy in anti-HBe-positive patients with chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2803%2900312-4

7 January 2021

Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2803%2900312-4

7 January 2021

Multicenter study of lamivudine therapy for hepatitis B after liver transplantation. Lamivudine Transplant Group.

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2803%2900312-4

7 January 2021

Adefovir dipivoxil alone or in combination with lamivudine in patients with lamivudine-resistant chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2803%2900312-4

7 January 2021

Interferon alfa for patients with clinically apparent cirrhosis due to chronic hepatitis B

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2803%2900312-4

7 January 2021

Low-dose, titratable interferon alfa in decompensated liver disease caused by chronic infection with hepatitis B virus

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2803%2900312-4

7 January 2021

A multicenter United States-Canadian trial to assess lamivudine monotherapy before and after liver transplantation for chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2803%2900312-4

7 January 2021

Lamivudine treatment for decompensated cirrhosis resulting from chronic hepatitis B

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2803%2900312-4

7 January 2021

Adefovir dipivoxil added to ongoing lamivudine in chronic hepatitis B with YMDD mutant hepatitis B virus

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2803%2900312-4

7 January 2021

Significance of hepatitis B genotype in acute exacerbation, HBeAg seroconversion, cirrhosis-related complications, and hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2803%2900312-4

7 January 2021

HIV-1, hepatitis B virus, and risk of liver-related mortality in the Multicenter Cohort Study (MACS).

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2803%2900312-4

7 January 2021

Effects of lamivudine on replication of hepatitis B virus in HIV-infected men.

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2803%2900312-4

7 January 2021

Long-term incidence of hepatitis B virus resistance to lamivudine in human immunodeficiency virus-infected patients

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2803%2900312-4

7 January 2021

Safety and efficacy of adefovir dipivoxil in patients co-infected with HIV-1 and lamivudine-resistant hepatitis B virus: an open-label pilot study

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2803%2900312-4

7 January 2021

Epidemiological factors affecting the severity of hepatitis C virus-related liver disease: a French survey of 6,664 patients. The Study Group for the Prevalence and the Epidemiology of Hepatitis C Virus

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2803%2900312-4

7 January 2021

The significance of antibody to hepatitis C virus in patients with chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2803%2900312-4

7 January 2021

Ribavirin and interferon is effective for hepatitis C virus clearance in hepatitis B and C dually infected patients

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2803%2900312-4

7 January 2021

Prophylaxis against chemotherapy-induced reactivation of hepatitis B virus infection with Lamivudine

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2803%2900312-4

7 January 2021

Lamivudine treatment during pregnancy to prevent perinatal transmission of hepatitis B virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2803%2900312-4

7 January 2021

Suppressing hepatitis B without resistance--so far, so good

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2803%2900312-4

7 January 2021

10.1016/S1542-3565(03)00312-4

Identifiers

DOI

1 reference

9 August 2017

1 reference